Peter Fellner to become new Chairman of Acambis
Advertisement
Acambis announces that, effective from 1 October 2006, Alan Smith will retire as Chairman, and from the Board, of Acambis and will be succeeded by Dr Peter Fellner.
Alan Smith, 61, has been Chairman of Acambis since May 1999, having joined the Board as a Non-executive Director in November 1995. During his tenure as Chairman, he has overseen the development of Acambis from a small research and development organisation into an international vaccine company capable of taking a product through all the stages of development to licensure. Mr Smith announced in May that, based on good corporate governance guidance that a director should reside on a board for no more than 10 years, he would be standing down later in 2006.
Dr Peter Fellner, 62, joined the Acambis Board as a Non-executive Director in February 2006. He was Celltech's Chief Executive Officer from 1990 to 2003 and Chairman from 2003 until its acquisition by the biopharmaceutical company, UCB SA, in 2004. He is Chairman of two other UK biotechnology companies, Vernalis plc and Astex Therapeutics Limited, and a Non-executive Director of QinetiQ Group plc, Evotec AG and Bespak plc. He is also a member of the UK Medical Research Council.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer - National Cancer Institute grants $1M to test 3 chemo drugs
Pioneering discovery of an odor-detecting receptor enhancer
Modified crops reveal hidden cost of resistance
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program - First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
UF study strengthens concerns about long-term use of certain painkillers
Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.
